Literature DB >> 10325536

Examination of potential inhibitors of hepatitis A virus uncoating.

N E Bishop1.   

Abstract

Hepatitis A virus (HAV) replication in BS-C-1 cells was studied in the presence of ten potential uncoating inhibitors. Strong inhibition of HAV replication was only observed in the presence of the phenothiazine compound chlorpromazine and the lysosomotropic agent chloroquine, but not by other lysosomotropic agents. Chlorpromazine and chloroquine were found to prevent virus uncoating. Chlorpromazine is known to inhibit endocytosis of non- clathrin-coated vesicles. Chloroquine is a weak base amine, and thought to inhibit virus replication by preventing endosomal acidification. These results therefore suggest that entry of HAV in BS-C-1 cells does not depend on the low pH encountered in the clathrin-coated endocytic entry pathway. A possible role of calcium ions in mediating viral uncoating is discussed, as calcium ions were found to destabilize HAV particles in vitro.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10325536     DOI: 10.1159/000024948

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  28 in total

1.  Uncoating kinetics of hepatitis A virus virions and provirions.

Authors:  N E Bishop; D A Anderson
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Picornaviruses.

Authors:  Tobias J Tuthill; Elisabetta Groppelli; James M Hogle; David J Rowlands
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  The VP4 peptide of hepatitis A virus ruptures membranes through formation of discrete pores.

Authors:  Ashutosh Shukla; Aditya K Padhi; James Gomes; Manidipa Banerjee
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

4.  A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy.

Authors:  W J Atwood
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 5.  Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.

Authors:  Anwar M Hashem; Badrah S Alghamdi; Abdullah A Algaissi; Fahad S Alshehri; Abdullah Bukhari; Mohamed A Alfaleh; Ziad A Memish
Journal:  Travel Med Infect Dis       Date:  2020-05-06       Impact factor: 6.211

6.  Phytochemical analysis and in-vitro anti-African swine fever virus activity of extracts and fractions of Ancistrocladus uncinatus, Hutch and Dalziel (Ancistrocladaceae).

Authors:  Folorunso O Fasina; Oyinlola O Olaokun; Olusola O Oladipo; Margaret M Fasina; Adesoji A Makinde; Livio Heath; Armanda D S Bastos
Journal:  BMC Vet Res       Date:  2013-06-19       Impact factor: 2.741

7.  Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses.

Authors:  Livia Di Trani; Andrea Savarino; Laura Campitelli; Sandro Norelli; Simona Puzelli; Daniela D'Ostilio; Edoardo Vignolo; Isabella Donatelli; Antonio Cassone
Journal:  Virol J       Date:  2007-05-03       Impact factor: 4.099

Review 8.  Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity.

Authors:  Hephzibah Akpovwa
Journal:  Cell Biochem Funct       Date:  2016-03-21       Impact factor: 3.685

Review 9.  The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway.

Authors:  Frédéric Carrière; Sonia Longhi; Michel Record
Journal:  Biochimie       Date:  2020-05-30       Impact factor: 4.079

Review 10.  Treatment of COVID 19-Repurposing drugs commonly used in dermatology.

Authors:  Jelena Stojkovic-Filipovic; Martina Bosic
Journal:  Dermatol Ther       Date:  2020-07-16       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.